Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Failed single-agent trial is small setback for Sutent, analyst says. Pfizer has three combination trials also ongoing in breast cancer settings.